** Shares of the U.S. drug developer  DOVA.O  jump 36.2% to
$27.50 premarket - set to open at highest level since June 2018 
    ** Dova shares currently trading at offer price of $27.50
per share  urn:newsml:reuters.com:*:nL5N26L12T 
    ** Rare diseases specialist Swedish Orphan Biovitrum (Sobi)
 SOBIV.ST  says it would grant the right to an additional $1.50
per share upon approval of Dova's blood disorder drug Doptelet
for use in chemotherapy-induced thrombocytopenia by the U.S. FDA
  
    ** Sobi agrees to buy Dova in a deal valuing Dova at up to
$915 mln 
    ** Upfront cash component represents a premium of 36% to
Dova's last closing price on Friday 
    ** Shares of Dova were the most actively traded across U.S.
exchanges before the bell 
    ** As of Friday's close, Dova shares have surged over 166%
this year 

 (Reporting by Shreyashi Sanyal in Bengaluru)
 ((Shreyashi.Sanyal@thomsonreuters.com; +1 646 223 8780))